Biogen Submits BLA for Investigational Alzheimer Disease Agent
Those who received the agent in EMERGE reported a significant slowing of decline on measures of cognition and function such as memory, orientation, and language, as well as for activities of daily living.
Read More
New Neurologic Symptoms Found in Children with COVID-19
Tests for N-methyl-Daspartate receptor, myelin oligodendrocyte glycoprotein, and aquaporin-4 autoantibodies had negative results in all patients.
Severe COVID-19 Outcomes for MS Patients Linked to Several Factors
The results echo the previous understanding of MS specialists as well as add to the literature that has been collected thus far from other assessments.
Healthy Lifestyle Aids in Alzheimer Disease Risk Reduction
Those with ≥150 min per week in moderated or vigorous activities were low risk while those with less than 150 or sedentary activity were higher risk.
Sudden Future: The Rise of Telemedicine During COVID-19
Our seven-part series on how the pandemic brought about telemedicine in US healthcare, and what its future use looks like.
Migraine History Linked to Concussion Severity
The frequency of attacks compared to monthly can directly increase the number and severity of post-concussion symptoms.
New Agents Available for Insomnia and Multiple Sclerosis
Recent studies show efficacy and safety for both lemborexant and ozanimod.
FDA Approves Tau Imaging Agent for Alzheimer Disease
The tau tracer can support a pathological diagnosis of Alzheimer disease by identifying the underlying presence of NFTs at the B3 level.
Investigators Tout New Alzheimer Disease Blood Immunoassay Test
The new technology has applications for diagnosis and recruitment for disease-modifying trials.
Preliminary Data Positive for Investigational Alzheimer Disease Agent
Despite patients being off treatment for an average of 23 months, patients treated with Eisai’s BAN2401 remained amyloid PET negative in an open-label extension preliminary analysis.
Positron Emission Tomography Tau Tracers Help to Diagnose Alzheimer Disease
Flortaucipir PET tracer’s can identify high levels of neuropathologic changes and neurofibrillary tangles.
FDA Approves Opicapone to Increase Parkinson Disease ON Time
The new approval is based on the result of 38 clinical trials involving more than 1000 patients.
Epilepsy Drug Reduces Anxiety and Insomnia Symptoms
New data finds perampanel lowers Insomnia Severity Index scores in patients.
Parkinson Disease Dementia Linked to Compulsive Behaviors
Impulse control disorder symptoms also commonly found in Parkinson disease patients treated with dopamine agonists.
New Migraine Treatment Prevents Pain Progression
AXS-07 showed statistical significance for migraine pain freedom at 90 minutes, and at every time point after.
Asymptomatic Sleep Disordered Breathing Could Forecast Alzheimer Disease
Better testing for SDB and other sleep disorders are needed for the older population.
Coronavirus and Ophthalmology Best Practices with Rishi Singh, MD
Rishi Singh, MD, of Cole Eye Institute, discusses steps to take to help prevent the spread of coronavirus in ophthalmology practices.
Janssen Submits NDA for New Multiple Sclerosis Drug
Ponesimod reduced fatigue-related symptoms in phase 3 clinical trial.
CDC, WHO Present Recommendations for Dealing with Stress of COVID-19
Individuals are encouraged to maintain some semblance of normalcy in face of the coronavirus outbreak, including regular exercise and sleep.
Stakeholders Discuss Impact of COVID-19 on MS Patients
Hospitals are preparing to treat MS patients safely in the wake of fears over the global pandemic.
Multiple Sclerosis Relapses Worsen Cognitive Impairment
MS patients who experience relapses score significantly lower on the Timed 25-Foot Walk Test.
Preparation Needed for Local Coronavirus Transmission, CDC Urges
The CDC is preparing for a hypothetical future despite American risk of local transmission not being high presently.
No New Recommendations for Cognitive Screenings in Older Adults
The task force’s recommendations will remain unchanged since the last version in 2014.
Apomorphine Helps Increase On Time Response for Parkinson Disease Patients
New drug more often linked to a full ON response from Parkinson disease patients at 30 minutes when compared to a placebo.
Extended-Release Amantadine Reduces Dyskinesia in Parkinson Disease Patients
Patients in the treatment group had improved dyskinesia symptoms and off time.
Flu Reaches 15 Million Americans in Current Season, CDC Reports
New weekly report data shows the count of jurisdictions with high influenza-like illness activity has risen again.